New York, Jan 28, 2026, 21:41 EST — Market closed.
- Thermo Fisher shares fell 2.55% to $608.02 on Wednesday, marking their second consecutive day of declines.
- The company will hold its Q4 2025 earnings call Thursday at 8:30 a.m. ET.
- Investors are grappling with mixed signals in life-science tools, following Danaher’s warning about soft academic research funding.
Thermo Fisher Scientific (TMO) shares dropped 2.55%, closing at $608.02 on Wednesday. The stock slipped for the second day as investors positioned ahead of the upcoming quarterly report. Trading volume reached around 2.3 million shares, surpassing the 50-day average. The stock now sits about 5.6% below its 52-week peak from Jan. 22. (MarketWatch)
Thermo Fisher set a conference call for 8:30 a.m. ET Thursday to go over its results and outlook. Investors are focused on the company’s forecast for 2026 demand, especially after a rocky run for health-care stocks. (Thermo Fisher Scientific)
The company occupies a key spot in the life-sciences supply chain, dealing in instruments and consumables and operating a sizable pharmaceutical services division. Its forecasts tend to sway the sector, particularly stocks linked to research and drug development.
Nasdaq.com data shows a consensus EPS estimate of $6.43 for Thermo Fisher for the quarter ending Dec. 31, 2025, up roughly 5% from last year. The company has beaten expectations in each of the previous four quarters. (Nasdaq)
Things got more complicated Wednesday after Danaher, a key competitor, topped quarterly profit forecasts and projected 2026 adjusted earnings between $8.35 and $8.50 per share, roughly matching Wall Street estimates. “Adjusted” figures typically exclude certain one-time charges. CEO Rainer Blair said Danaher “delivered a strong finish to the year” but flagged weakness in academic research funding, a concern for suppliers tied to university and government lab budgets. (Reuters)
U.S. stocks closed mostly flat after the Federal Reserve held interest rates steady at 3.5% to 3.75%. The S&P 500 slipped 0.01%, while the Nasdaq gained 0.17%. Michael James, an equity sales trader at Rosenblatt Securities, noted, “Whether you were bullish or bearish going into the press conference you walked away feeling about the same.” (Reuters)
Life-science tools stocks took a hit during the session. Danaher dropped 4.76%, Agilent Technologies was down 1.53%, and Thermo Fisher slid 2.55%. (MarketWatch)
Investors in Thermo Fisher will zero in on management’s comments regarding order trends in bioprocessing and contract development and manufacturing, as well as demand for lab products and services. Updates on China remain a crucial wildcard for the sector and are expected to spark questions.
The report arrives amid a packed earnings slate for U.S. blue chips, a backdrop that often fuels sector rotation. Volatility tends to spike when guidance deviates from expectations.
Thursday’s earnings and the 8:30 a.m. ET call are next. Investors will be probing for a sharper 2026 outlook and any hints that demand at the end market is steadying.
